Equities
  • Price (EUR)145.92
  • Today's Change-1.12 / -0.76%
  • Shares traded0.00
  • 1 Year change+8.41%
  • Beta--
Data delayed at least 15 minutes, as of Nov 30 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics business includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. Its Agilent CrossLab business spans the entire lab with its range of services portfolio, which is designed to improve customer outcomes. Its product categories include liquid chromatography (LC) systems and components, atomic absorption (AA) instruments and others.

  • Revenue in USD (TTM)6.85bn
  • Net income in USD1.25bn
  • Incorporated1999
  • Employees17.70k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 345-8296
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
announced
Transaction
value
PSS Polymer Standards Service GmbHDeal completed02 Aug 202202 Aug 2022Deal completed16.97%--
Data delayed at least 15 minutes, as of Dec 01 2022 16:58 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.